GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Net Income Including Noncontrolling Interests
中文

SK Bioscience Co (XKRX:302440) Net Income Including Noncontrolling Interests : ₩22,318 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

SK Bioscience Co's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was ₩4,170 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was ₩22,318 Mil.

SK Bioscience Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for SK Bioscience Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Net Income Including Noncontrolling Interests Chart

SK Bioscience Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial 14,677.41 32,889.71 355,139.28 122,451.95 22,317.72

SK Bioscience Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27,741.56 -14,267.86 -15,976.00 48,391.96 4,169.61

SK Bioscience Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩22,318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SK Bioscience Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XKRX:028300 XKRX:326030 XKRX:196170 XKRX:145020 XKRX:048410 XKRX:086900 XKRX:214450 XKRX:141080 XKRX:096530 XKRX:085660 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
Website
https://www.skbioscience.co.kr
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines